Evaluation of the performance of GeneSoC®, a novel rapid real-time PCR system, to detect Staphylococcus aureus and methicillin resistance in blood cultures

• Published in: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy Vol. 29; no. 7; pp. 718 - 721
• Main Authors: Chiba, Mikiko, Aoyagi, Tetsuji, Yoshida, Makiko, Katsumi, Makoto, Fujimaki, Shin-ichi, Ishii, Yoshikazu, Tateda, Kazuhiro, Kaku, Mitsuo
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.07.2023
• Subjects: Bacterial Proteins - genetics; Blood Culture; Blood culture testing; Diagnostics; Humans; Methicillin - pharmacology; Methicillin - therapeutic use; Methicillin Resistance - genetics; Methicillin-Resistant Staphylococcus aureus - genetics; MRSA; MSSA; Pilot Projects; qPCR; Real-Time Polymerase Chain Reaction; Staphylococcal Infections - drug therapy; Staphylococcus aureus - genetics; MSSA; Blood culture testing; qPCR; Diagnostics; MRSA
• ISSN: 1341-321X; 1437-7780
• DOI: 10.1016/j.jiac.2023.03.006

Staphylococcus aureus bacteremia results in substantial mortality. Rapid identification and the determination of methicillin susceptibility are crucial for immediate treatment with appropriate antibiotics. In the present study, we aimed to evaluate the basic assay performance of GeneSoC®, a novel rapid quantitative polymerase chain reaction (qPCR) method, for the detection of methicillin-susceptible (MS) or -resistant (MR) S. aureus in blood culture (BC) bottles. qPCR pimers and probes were desinged for femA and mecA genes to diagnose S. aureus and its methicilline-resistance status. GeneSoC® system can detect target genes within 12 min per sample using microfludic thermal cycling. A total of 100 BC-positive samples, showing clusters of gram-positive cocci using microscopy, were tested. The analytical sensitivity was demonstrated for the target sequence of femA and mecA genes at 10 copies/μL, respectively. The detection limit of the MRSA bacterial burden using this system was 104 and 103 CFU/mL for femA and mecA, respectively. Compared with culture-based identification and susceptibility testing, the sensitivity and specificity for the detection of femA (+)/mecA (+) MRSA using GeneSoC® were 90.9 and 98.9%, respectively, whereas the sensitivity and specificity for detection of femA (+)/mecA (-) MSSA were 96.2% and 97.3%, respectively. In conclusion, although this was a small sample and pilot study, the GeneSoC® system is beneficial for rapid, reliable, and highly sensitive real-time testing of MRSA and MSSA in BC bottles.